Search results
Results from the WOW.Com Content Network
Antidepressant discontinuation syndrome, also called antidepressant withdrawal syndrome, is a condition that can occur following the interruption, reduction, or discontinuation of antidepressant medication following its continuous use of at least a month. [5]
Stopping imipramine (Tofranil), paroxetine (Paxil or Seroxat), and venlafaxine (Effexor)/ desvenlafaxine (Pristiq) was associated with a higher risk of severe symptoms compared to other ...
Paroxetine, sold under the brand name Paxil among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. [7] It is used to treat major depressive disorder, obsessive–compulsive disorder (OCD), panic disorder, social anxiety disorder, post-traumatic stress disorder (PTSD), generalized anxiety disorder, and premenstrual dysphoric disorder. [7]
Symptoms typically persist for a longer time frame in patients taking drugs which have a long elimination half-life, active metabolites, or a protracted duration of action. [ 6 ] Cases have reported persisting chronic symptoms, [ 75 ] and antidepressant discontinuation may contribute to ongoing features. [ 76 ]
Online, people claim they get brain zaps after stopping use of drugs like Lexapro (escitalopram), Cymbalta (duloxetine), and Paxil (paroxetine), but they can happen when you stop taking any type ...
Fluoxetine also has a long half-life which can reduce withdrawal symptoms which are characteristic for some SSRIs after abrupt discontinuation, but it also means that it takes a long time to clear the drug and its active metabolite after discontinuing fluoxetine treatment. [18] Figure 5 Chemical structure of (–)-(3S,4R)-paroxetine
The Dry January campaign was started in 2013 by Alcohol Change U.K., a charity focused on reducing alcohol harm. What are the health benefits of Dry January? While research on how quitting alcohol ...
Where risks or harms is the reason for withdrawal, this will usually have been prompted by unexpected adverse effects that were not detected during Phase III clinical trials, i.e. they were only made apparent from postmarketing surveillance data collected from the wider community over longer periods of time.